AIDS Healthcare Foundation Files Shareholder Proposal Urging Gilead Sciences to Increase Transparency on Patent Exclusivity Practices
Access to life-saving medicines remains one of the most critical challenges in global healthcare, and for many advocates, the issue extends far beyond scientific innovation. Even the most effective therapies lose their value if they remain financially or logistically out of reach for patients who need them. This concern is now at the center of growing scrutiny surrounding Gilead Sciences, as shareholders prepare for the company’s annual general meeting scheduled for April 30, 2026. At this meeting, stakeholders will consider a proposal aimed at increasing transparency in how the company manages its drug development and patent strategies.
The proposal, filed by the AIDS Healthcare Foundation (AHF), calls on Gilead’s Board of Directors to produce a detailed report assessing the potential risks associated with extending patent exclusivity on existing drugs. Specifically, Proposal 6 raises concerns that such strategies could delay the introduction of breakthrough therapies and biosimilars, ultimately restricting patient access to newer, more effective, or more affordable treatment options. For AHF and other advocates, the issue is not simply about intellectual property rights—it is about whether corporate decision-making aligns with broader public health priorities.
Patent exclusivity has long been a contentious issue in the pharmaceutical industry. While it is intended to reward innovation and allow companies to recoup research and development investments, critics argue that it is often used to extend market dominance beyond reasonable limits. In the case of Gilead, AHF contends that these practices may be slowing the pace at which improved therapies reach patients, particularly in areas such as HIV treatment where rapid advancements have the potential to significantly improve quality of life and long-term outcomes.
Adding to these concerns is the pricing strategy surrounding some of Gilead’s most widely used medications. Despite ongoing fiscal pressures faced by public health programs, including state-run AIDS Drug Assistance Programs (ADAPs) in the United States, the company has been accused of maintaining or planning price increases for drugs supplied to these programs. Although Gilead refrained from implementing price hikes in the previous year, advocates argue that the possibility of future increases continues to create uncertainty and strain on already limited healthcare budgets.
At the same time, Gilead’s financial performance paints a picture of stability and growth. The company recently reported a 5% increase in sales of Biktarvy during the fourth quarter of 2025, with the drug generating approximately $4 billion in revenue. Widely regarded as a leading treatment option for people living with HIV due to its efficacy and safety profile, Biktarvy has become a cornerstone of modern HIV care. However, its high cost has also made it a focal point in debates about affordability and equitable access.
The implications of these pricing dynamics are already being felt at the state level. In Florida, for example, rising drug costs have contributed to a financial crisis within the ADAP system. According to advocates, sustained pricing pressures forced the program to implement difficult measures, including lowering the income eligibility threshold for patients and removing Biktarvy from the state’s approved formulary. In its place, the program has turned to Truvada, an older therapy also developed by Gilead.
While Truvada has played a significant role in HIV treatment and prevention over the years, it is generally considered less advanced than newer therapies. Some clinicians and patient advocates have raised concerns about its side effect profile, including potential impacts on bone density and kidney function in certain individuals. The shift toward older, less expensive medications highlights the difficult trade-offs that healthcare systems must make when faced with budget constraints—trade-offs that can directly affect patient outcomes.
For AHF, these developments underscore the urgent need for greater accountability and transparency within the pharmaceutical industry. As the world’s largest HIV/AIDS healthcare organization, AHF provides medical care and advocacy services to more than 2.9 million people across 50 countries, spanning regions such as the United States, Africa, Latin America and the Caribbean, the Asia-Pacific, and Eastern Europe. Its work focuses not only on delivering treatment but also on addressing systemic barriers that limit access to care.
The organization’s efforts have earned international recognition, including the prestigious MLK Jr. Social Justice Award, which it received in January 2025. This honor reflects AHF’s broader mission to advance health equity and social justice, particularly for underserved populations disproportionately affected by HIV/AIDS.
As Gilead’s annual meeting approaches, the debate surrounding Proposal 6 is likely to draw significant attention from investors, policymakers, and public health advocates alike. At its core, the discussion raises fundamental questions about the balance between innovation, profitability, and patient access. While pharmaceutical companies play a vital role in developing life-saving therapies, their decisions also have far-reaching consequences for healthcare systems and the individuals who depend on them.
Ultimately, the outcome of this proposal may serve as an important indicator of how the industry responds to growing calls for transparency and accountability. Whether or not the measure is adopted, it highlights an ongoing tension within modern healthcare: ensuring that scientific progress translates into real-world benefits for all patients, not just those who can afford it.
Source Link:https://www.businesswire.com/
